US Patent Issued to Cellectis on Oct. 6 for "Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy" (French Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,220, issued on Oct. 6, was assigned to Cellectis (Paris).

"Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy" was invented by Cecile Schiffer-Mannioui (Villiers-sur-marne, France) and Philippe Duchateau (Saint Louis et Parahou, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to engineered immune cells expressing new mesothelin (MLSN) specific chimeric antigen receptors (anti-mesothelin CAR) and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy."

The patent was filed on Dec. 22, 2020, under Application No. 17/788,133.

*For fur...